All the news Showing 10 of 926 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment for people who use drugs Peer-led recruitment improves hepatitis C screening in people who use drugs Keith Alcorn / 25 July 2022 A peer-led recruitment strategy proved highly successful in engaging people who use drugs in testing and treatment for hepatitis C in the French city of Montpellier, researchers from the University of Montpellier report ... Kidney disease & HCV Higher kidney disease risk persists in people cured of hepatitis C Keith Alcorn / 19 July 2022 People with hepatitis C remain at higher risk of chronic kidney disease after clearing or being cured of hepatitis C and people with genotype 1 infection have a higher risk of kidney ... Starting treatment Why do people with HIV delay hepatitis C treatment? Keith Alcorn / 15 July 2022 Greater efforts by healthcare providers to build trusting relationships with people with HIV and hepatitis C, together with a greater focus on overcoming concerns about treatment side effects, are likely to be needed ... New and experimental treatments for hepatitis B Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies Keith Alcorn / 29 June 2022 Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ... Hepatitis D Bulevirtide leads to sustained improvement for people with hepatitis D Liz Highleyman / 28 June 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ... New and experimental treatments for hepatitis B Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Keith Alcorn / 27 June 2022 People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ... Treatment for previous non-responders & relapsers Re-treatment of hepatitis C is highly effective after the first combination fails Keith Alcorn / 24 June 2022 Two combinations proved highly effective in curing hepatitis C in people who had experienced the failure of a previous combination containing an NS5A inhibitor, studies in Europe and New Zealand show. The findings, ... Treatment in liver transplanted Short-course treatment prevents hepatitis C after organ transplant Keith Alcorn / 24 June 2022 A seven-day course of direct-acting antiviral treatment started hours before an organ transplant prevented hepatitis C infection in everyone who received a transplant from a donor with hepatitis C, researchers from the Mayo ... Life after the cure People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes Keith Alcorn / 24 June 2022 People who have been cured of hepatitis C remain at higher risk of dying from liver-related causes than the general population, but their risk of cardiovascular events goes down after being cured, ... Promoting hepatitis testing Self-sampling for hepatitis C improves diagnosis rate in the Netherlands Keith Alcorn / 01 June 2022 Online risk assessment for hepatitis C and home-based sampling for HCV-RNA testing proved acceptable, easy to use and resulted in a high rate of diagnosis of chronic hepatitis C infections among gay ... ← First12345...93Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds